|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics
Datamonitor, Nov 2010, Pages: 297
Introduction
The treatment of moderate to severe acute pain is dominated by opioids. While they offer excellent pain relief, they come with undesirable side effects and abuse potential. The future market is highly receptive to better tolerated opioids and analgesics with opioid-sparing effects. Opportunities also exist in the post-operative and breakthrough pain segments for rapid acting delivery technologies.
Features and benefits
- Analysis of patient segmentation, epidemiology, current treatment approaches, the patient acquisition process and clinical unmet needs
- Assessment of key pipeline agents in late stage development for breakthrough, post-operative, and general moderate to severe acute pain treatment
- Breakdown of historic (2005-09) and future (2010-19) prescription sales across the seven major markets consisting of the US, Japan, and 5EU.
- Discussion of pipeline trends, R&D strategies, and key development companies
Highlights
- The value of the moderate-to-severe acute pain market across the seven major markets was $3.9 billion in 2009 and is forecast to reach $6.1 billion by 2019. Current pipeline drugs are expected to drive future market growth and will constitute almost one quarter of the market by 2019.
- The prevailing strategy employed by developers of acute pain treatments is that of reformulating alternative delivery methods of established opioid molecules. Although this is less risk with this strategy the rewards are not substantial, particularly in this cost competitive market environment.
- The market is receptive to analgesics offering fewer adverse events than opioids and have opioid-sparing effects. Several pipeline products appear promising, such as QRx Pharma's dual opioid combination MoxDuo and Nycomed/Durect's long acting bupivacaine injection Posidur. However, convincing clinical data is needed to aid market penetration.
Your key questions answered
- Who will be the winners and losers in the future breakthrough cancer pain market?
- What are the commercial prospects for non-opioid analgesics, such as ketamine and bupivacaine, targeting moerate to severe acute pain?
- What are the most promising drug candidates in development for the potential treatment of post-operative pain?
|
|
|
|
